S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
BREAKING: Tiny biotech successfully treats blindness (Ad)
Gunmen kill 9 Chinese at mine in Central African Republic
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Bank Accounts: Frozen! (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
Nations approve key UN science report on climate change
"Prepare for Five Years of Famine" (Ad)
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
BREAKING: Tiny biotech successfully treats blindness (Ad)
Gunmen kill 9 Chinese at mine in Central African Republic
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Bank Accounts: Frozen! (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
Nations approve key UN science report on climate change
"Prepare for Five Years of Famine" (Ad)
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
BREAKING: Tiny biotech successfully treats blindness (Ad)
Gunmen kill 9 Chinese at mine in Central African Republic
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Bank Accounts: Frozen! (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
Nations approve key UN science report on climate change
"Prepare for Five Years of Famine" (Ad)
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
BREAKING: Tiny biotech successfully treats blindness (Ad)
Gunmen kill 9 Chinese at mine in Central African Republic
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Bank Accounts: Frozen! (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
Nations approve key UN science report on climate change
"Prepare for Five Years of Famine" (Ad)
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
OTCMKTS:OPHLF

Ono Pharmaceutical - OPHLF Stock Forecast, Price & News

$20.50
-0.04 (-0.19%)
(As of 03/15/2023)
Add
Compare
Today's Range
$20.50
▼
$20.50
50-Day Range
$20.25
▼
$22.60
52-Week Range
$20.25
▼
$27.76
Volume
100 shs
Average Volume
1,560 shs
Market Capitalization
$10.54 billion
P/E Ratio
14.04
Dividend Yield
N/A
Price Target
N/A

OPHLF stock logo

About Ono Pharmaceutical (OTCMKTS:OPHLF) Stock

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

Receive OPHLF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

OPHLF Stock News Headlines

January 27, 2023 | msn.com
USFDA gives exception to Glenmark Pharma to supply pneumonia drug from Baddi facility
December 15, 2022 | technews.tmcnet.com
PrecisionLife Enters into a Multi Target R&D Collaboration Agreement with Ono Pharmaceutical
March 20, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
December 14, 2022 | msn.com
PrecisionLife and Ono Pharmaceutical enter multi-year collaboration
August 3, 2022 | seekingalpha.com
Ono Pharmaceutical GAAP EPS of ¥60.36, revenue of ¥106.72B
June 28, 2022 | seekingalpha.com
Fate, Ono expand team up on cancer immunotherapy program
June 10, 2022 | finance.yahoo.com
Ono Pharmaceutical Co. (OPHLF) Upgraded to Strong Buy: What Does It Mean for the Stock?
January 7, 2022 | nasdaq.com
Ono Pharmaceutical Co. Ltd (OPHLF)
March 20, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
November 13, 2021 | markets.businessinsider.com
Here's what Wall Street expects from Ono Pharmaceutical's earnings
July 28, 2021 | markets.businessinsider.com
Here's what Wall Street expects from Ono Pharmaceutical's earnings report
March 23, 2021 | msn.com
Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients
January 31, 2021 | markets.businessinsider.com
Here's what to expect from Ono Pharmaceutical's earnings
December 26, 2020 | markets.businessinsider.com
News for Ono Pharmaceutical
December 18, 2020 | seekingalpha.com
Fate Therapeutics Jumped On Supportive Trial Data
October 2, 2020 | seekingalpha.com
Gilead's Cancer Follies
August 16, 2020 | ca.finance.yahoo.com
Ono Pharmaceutical Co., Ltd. (OPHLF)
August 2, 2020 | www.nasdaq.com
Ono Pharmaceutical Co Ltd (Japan) (OPHLF)
September 28, 2019 | www.nasdaq.com
Ono Pharmaceutical Co Ltd (Japan) (OPHLF) Short Interest
July 18, 2019 | seekingalpha.com
Fate Therapeutics: Updates To Thesis, Gaining Momentum In The Clinic
March 26, 2019 | www.marketwatch.com
Vect-Horus enters into Collaboration and License Agreement with Ono Pharmaceutical Co., Ltd.
March 18, 2019 | www.businesswire.com
Ono Pharmaceutical and twoXAR Announce Drug Discovery Research Collaboration
See More Headlines
Receive OPHLF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

OPHLF Company Calendar

Today
3/20/2023
Fiscal Year End
3/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:OPHLF
CUSIP
N/A
CIK
940821
Web
www.ono.co.jp
Phone
(166) 263-5670
Fax
816-6263-2950
Employees
3,687
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
$1.46
Trailing P/E Ratio
14.04
Forward P/E Ratio
10.85
P/E Growth
N/A
Net Income
$716.61 million
Net Margins
22.43%
Pretax Margin
N/A
Return on Equity
12.56%
Return on Assets
11.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.16
Quick Ratio
3.59

Sales & Book Value

Annual Sales
$3.22 billion
Price / Sales
3.27
Cash Flow
$1.70 per share
Price / Cash Flow
12.05
Book Value
$11.45 per share
Price / Book
1.79

Miscellaneous

Outstanding Shares
514,120,000
Free Float
N/A
Market Cap
$10.54 billion
Optionable
Not Optionable
Beta
0.41

Key Executives

  • Mr. Gyo Sagara (Age 64)
    CEO, Pres & Representative Director
  • Mr. Shozo Matsuoka Ph.D.
    Corp. Exec. Officer and Exec. Director of Corp. Regulatory Compliance, Safety & QA
  • Yukio Tani
    Corp. Exec. Officer & Head of Corp. Communications
  • Katsuji Teranishi
    Corp. Officer and Chief Officer of Sales, Mkt, Wholesales Mgt., Planning & Primary Care Bus. Div.
  • Mr. Isao Ono (Age 63)
    Exec. Officer, Director of Corp. Research & Director
  • Mr. Hiroshi Ichikawa
    Corp. Officer & Sr. Director of Medical External Affairs
  • Mr. Toichi Takino Ph.D. (Age 54)
    Sr. Exec. Officer, Exec. Director of Discovery & Research and Director
  • Mr. Toshihiro Tsujinaka (Age 58)
    Sr. Exec. Officer, Exec. Director of Corp. Strategy & Planning and Director
  • Hiromu Habashita Ph.D.
    Corp. Officer and Deputy Exec. Director of Discovery & Research Division
  • Kiyoaki Idemitsu (Age 58)
    Exec. Officer, Exec. Director of Clinical Devel. & Director

Key Competitors

View All Competitors













OPHLF Stock - Frequently Asked Questions

How have OPHLF shares performed in 2023?

Ono Pharmaceutical's stock was trading at $23.21 at the beginning of 2023. Since then, OPHLF stock has decreased by 11.7% and is now trading at $20.50.
View the best growth stocks for 2023 here.

What is Ono Pharmaceutical's stock symbol?

Ono Pharmaceutical trades on the OTCMKTS under the ticker symbol "OPHLF."

How do I buy shares of Ono Pharmaceutical?

Shares of OPHLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ono Pharmaceutical's stock price today?

One share of OPHLF stock can currently be purchased for approximately $20.50.

How much money does Ono Pharmaceutical make?

Ono Pharmaceutical (OTCMKTS:OPHLF) has a market capitalization of $10.54 billion and generates $3.22 billion in revenue each year. The company earns $716.61 million in net income (profit) each year or $1.46 on an earnings per share basis.

How many employees does Ono Pharmaceutical have?

The company employs 3,687 workers across the globe.

How can I contact Ono Pharmaceutical?

Ono Pharmaceutical's mailing address is 8-2 Kyutaromachi 1-chome Chuo-ku, Osaka M0, 541-8564. The official website for the company is www.ono.co.jp. The company can be reached via phone at (166) 263-5670 or via fax at 816-6263-2950.

This page (OTCMKTS:OPHLF) was last updated on 3/20/2023 by MarketBeat.com Staff